Knowledge base
1,246 claims across 14 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,246ai alignment 318internet finance 256health 201space development 171entertainment 127grand strategy 101energy 23mechanisms 18collective intelligence 14manufacturing 5robotics 5critical systems 3unknown 3teleological economics 1
AI-induced upskilling inhibition prevents skill acquisition in trainees through routine case reduction creating a distinct never-skilling pathway
This mixed-method review introduces 'upskilling inhibition' as a distinct concept from deskilling. While deskilling affects experienced practitioners who lose skills through disuse, upskilling inhibition affects trainees who never acquire skills in the first place. The mechanism: AI systems handle r
Clinical AI creates moral deskilling through ethical judgment erosion from routine AI acceptance leaving clinicians unprepared to recognize value conflicts
This review introduces 'moral deskilling' as a distinct form of AI-induced competency loss separate from cognitive deskilling. The mechanism: repeated acceptance of AI recommendations creates habituation that reduces ethical sensitivity and moral judgment capacity. Clinicians become less prepared to
Clinical AI deskilling is a generational risk affecting future trainees rather than current practitioners because experienced clinicians retain pre-AI skill foundations while new trainees face never-skilling in AI-saturated environments
The ARISE 2026 report synthesizing 2025 clinical AI research documents a critical temporal distinction in deskilling risk. Current practicing clinicians report NO measurable deskilling from AI applications, which the report attributes to their pre-AI clinical training providing a skill foundation th
Clinical AI upskilling requires deliberate educational mechanisms and workflow design rather than occurring automatically from AI exposure
The ARISE 2026 report challenges the assumption that AI assistance automatically produces upskilling through time liberation. While the report confirms that 'current AI applications function primarily as assistants rather than autonomous agents, offering an opportunity for upskilling by liberating c
Economic downturns reduce pollution-related mortality primarily in elderly populations through air quality improvement while simultaneously increasing deaths of despair among working-age populations
A 1 percentage point increase in commuting zone unemployment rate during the 2007-2009 Great Recession was associated with a 0.5% decrease in age-adjusted mortality rate, implying a 2.3% reduction in average annual mortality for a recession-sized unemployment shock. However, this aggregate finding m
Moral deskilling from AI erodes ethical judgment through repeated cognitive offloading creating a safety risk distinct from diagnostic accuracy
The paper introduces 'moral deskilling' as a distinct category of AI-induced harm separate from diagnostic deskilling. While diagnostic deskilling affects clinical accuracy (forming differential diagnoses, physical examination skills), moral deskilling affects ethical judgment capacity. The mechanis
Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
A 9-week double-blind RCT (n=48) demonstrated that semaglutide produces clinically significant reductions in alcohol consumption through the same VTA dopamine reward circuit mechanism that drives its metabolic effects. The trial showed dose-response escalation: small-to-medium effects at 0.25mg (wee
The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
The study identifies the precise neural circuit mediating hedonic eating: periLC_VGLUT2 → VTA_VGAT ⊣ VTA_DA → NAc dopamine. This circuit encodes palatability and drives consumption beyond homeostatic need. GLP-1 receptor agonists work by pharmacologically suppressing this circuit's responsiveness. T
GLP-1 appetite suppression creates a protein deficiency pathway that causes muscle loss, making resistance training mechanistically necessary rather than complementary
GLP-1 receptor agonists produce greater short-term weight loss than exercise alone, but this pharmacological advantage creates a specific risk: appetite suppression and reduced gastric emptying limit protein intake and nutrient absorption necessary for muscle preservation. The review identifies resi
GLP-1 obesity coverage creates acute payer fiscal crisis with employer plans experiencing >10x PMPM cost increases in 2023-2024 and major insurers reporting operating losses driven primarily by GLP-1 expenditures
ICER's April 2025 white paper documents that self-insured employers offering GLP-1 obesity coverage experienced >10x increase in per-member, per-month (PMPM) costs from January 2023 to December 2024. Blue Cross Blue Shield of Massachusetts ended 2024 with a $400 million operating loss, with GLP-1 dr
GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
A systematic review of ClinicalTrials.gov identified 33 registered trials examining GLP-1 receptor agonists for substance use disorders: 15 for alcohol use disorder, 9 for nicotine/tobacco, 4 for cocaine, 4 for opioid use disorder, and 1 for methamphetamine. The mechanistic basis is shared with obes
Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
Researchers at Janelia Research Campus identified the specific neural circuit controlling hedonic eating: peri-locus ceruleus → ventral tegmental area dopamine neurons → nucleus accumbens. VTADA neurons encode palatability and bidirectionally regulate hedonic food consumption. Critically, semaglutid
Hospital-physician consolidation consistently increases prices without improving quality as price effects are confirmed while quality evidence is mixed-to-negative across four years of literature
The GAO reviewed peer-reviewed studies published between January 2021 and July 2025, finding that hospital-physician consolidation produces consistent price increases but quality outcomes that are 'same or lower' after consolidation. The report states that 'studies show consolidation can increase sp
WHO's GLP-1 guideline rates behavioral interventions as optional supplements with only low-certainty evidence that they enhance pharmacological outcomes
WHO's December 2025 GLP-1 guideline includes a secondary recommendation that intensive behavioral interventions (structured healthy diet + physical activity + professional support) 'may be offered' to adults taking GLP-1s for obesity. Critically, this recommendation is based on 'low-certainty eviden
WHO's December 2025 GLP-1 guideline marks the first global endorsement of pharmacological obesity treatment but its conditional status signals inadequate health system readiness and unresolved equity concerns
On December 1, 2025, WHO issued its first-ever global guideline on GLP-1 medicines for obesity treatment, covering liraglutide, semaglutide, and tirzepatide. Critically, the recommendation is conditional rather than strong. WHO explicitly states the conditional status is driven by: (1) limited data
AI-defined case routing prevents trainees from developing threshold-setting skills required for independent practice
The paper notes that 'only human experts can revise the thresholds for case prioritization'—but this statement reveals a deeper problem: AI defines what humans see in the first place. When trainees are trained under an AI threshold system, they encounter only the cases the AI routes to them. This pr
AI-integrated cervical cytology screening reduces trainee exposure to routine cases creating never-skilling risk for foundational pattern recognition skills
AI automation in cervical cytology screening targets 'routine processes, such as initial screenings and pattern recognition in straightforward cases' for efficiency gains. However, these routine cases are precisely where trainees develop foundational pattern recognition skills. As AI handles large v
AI micro-learning loop creates durable upskilling through review-confirm-override cycle at point of care
Oettl et al. propose that AI creates a 'micro-learning at point of care' mechanism where clinicians must 'review, confirm or override' AI recommendations, which they argue reinforces diagnostic reasoning rather than causing deskilling. This is the theoretical counter-mechanism to the deskilling thes
Federal GLP-1 expansion programs reproduce the access hierarchy at the program design level, not just through market dynamics
The Medicare GLP-1 Bridge program demonstrates that the GLP-1 access inversion operates at the program design level, not just the market level. While the program was designed to 'expand access' to GLP-1 obesity medications, its legal architecture—required because Medicare is statutorily prohibited f
State Medicaid budget pressure is actively reversing GLP-1 obesity coverage gains with California and three other states eliminating coverage in 2025-2026
As of January 2026, only 13 states (26% of state programs) cover GLP-1s for obesity under fee-for-service Medicaid, but critically, four states have actively eliminated existing coverage due to budget pressure: California, New Hampshire, Pennsylvania, and South Carolina. California's Medi-Cal projec
The Medicare GLP-1 Bridge program's Low-Income Subsidy exclusion structurally denies the lowest-income Medicare beneficiaries access to GLP-1 obesity coverage despite nominal eligibility
The Medicare GLP-1 Bridge program (July-December 2026) covers Wegovy and Zepbound at a fixed $50 copayment for eligible Part D beneficiaries. However, the program contains a critical structural flaw: Low-Income Subsidy (LIS) cost-sharing subsidies will not apply to GLP-1 prescriptions filled under t
Never-skilling affects trainees while deskilling affects experienced physicians creating distinct population risks with different intervention requirements
Oettl et al. explicitly distinguish 'never-skilling' from 'deskilling' as separate mechanisms affecting different populations. Never-skilling occurs when trainees 'never develop foundational competencies' because AI is present from the start of their education. Deskilling occurs when experienced phy
Never-skilling is mechanistically distinct from deskilling because it affects trainees who lack baseline competency rather than experienced physicians losing existing skills
Oettl et al. explicitly distinguish 'never-skilling' from deskilling as separate mechanisms with different populations and dynamics. Deskilling affects experienced physicians who have baseline competency and lose it through AI reliance. Never-skilling affects trainees who never develop foundational
Audio-only telehealth is the equity-relevant modality because it over-indexes on populations that video-based telehealth systematically underserves
Among telehealth modalities, audio-only demonstrates a distinct equity profile. Medicare beneficiaries who are older, racial/ethnic minorities, dual-enrolled, rural, or have low broadband access are significantly more likely to use audio-only than video-based telehealth. This pattern inverts the typ
Culturally adapted digital mental health interventions achieve double the effect size for racial/ethnic minorities compared to standard apps
The JMIR 2024 meta-analysis found that culturally adapted digital mental health interventions achieve an effect size of g=0.90 for racial/ethnic minorities, compared to g=0.43 for standard apps—a 2.1x improvement. This suggests that the widely documented efficacy gap for digital mental health in min
Page 1 of 9